Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.95 - $4.04 $1,950 - $4,040
-1,000 Reduced 33.21%
2,011 $5,000
Q4 2023

Feb 15, 2024

SELL
$2.32 - $5.51 $24,056 - $57,133
-10,369 Reduced 77.5%
3,011 $8,000
Q3 2023

Nov 14, 2023

SELL
$2.49 - $11.85 $12,621 - $60,067
-5,069 Reduced 27.48%
13,380 $33,000
Q2 2023

Aug 14, 2023

BUY
$6.39 - $28.58 $54,743 - $244,844
8,567 Added 86.69%
18,449 $122,000
Q1 2023

May 15, 2023

BUY
$17.7 - $33.24 $3,610 - $6,780
204 Added 2.11%
9,882 $184,000
Q4 2022

Feb 14, 2023

BUY
$10.25 - $22.43 $6,949 - $15,207
678 Added 7.53%
9,678 $207,000
Q3 2022

Nov 14, 2022

BUY
$11.19 - $17.89 $3,368 - $5,384
301 Added 3.46%
9,000 $107,000
Q2 2022

Aug 22, 2022

BUY
$9.03 - $21.55 $2,763 - $6,594
306 Added 3.65%
8,699 $114,000
Q1 2022

May 16, 2022

BUY
$15.0 - $22.83 $1,185 - $1,803
79 Added 0.95%
8,393 $176,000
Q3 2021

Nov 15, 2021

BUY
$23.84 - $32.03 $94,454 - $126,902
3,962 Added 91.04%
8,314 $252,000
Q2 2021

Aug 12, 2021

BUY
$29.06 - $38.83 $5,812 - $7,766
200 Added 4.82%
4,352 $127,000
Q1 2021

May 17, 2021

SELL
$39.04 - $64.6 $2,810 - $4,651
-72 Reduced 1.7%
4,152 $179,000
Q4 2020

Feb 12, 2021

BUY
$42.46 - $56.58 $101,352 - $135,056
2,387 Added 129.94%
4,224 $195,000
Q3 2020

Nov 13, 2020

SELL
$37.44 - $64.63 $12,804 - $22,103
-342 Reduced 15.7%
1,837 $80,000
Q2 2020

Aug 14, 2020

BUY
$17.62 - $58.71 $19,681 - $65,579
1,117 Added 105.18%
2,179 $116,000
Q1 2020

May 14, 2020

SELL
$12.26 - $41.14 $2,059 - $6,911
-168 Reduced 13.66%
1,062 $24,000
Q4 2019

Feb 13, 2020

BUY
$4.05 - $14.61 $911 - $3,287
225 Added 22.39%
1,230 $18,000
Q2 2019

Aug 14, 2019

BUY
$8.99 - $11.79 $9,034 - $11,848
1,005 New
1,005 $11,000

Others Institutions Holding BTAI

About BioXcel Therapeutics, Inc.


  • Ticker BTAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,022,500
  • Market Cap $83.5M
  • Description
  • BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...
More about BTAI
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.